203 related articles for article (PubMed ID: 35756176)
21. Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer.
Faivre EJ; McDaniel KF; Albert DH; Mantena SR; Plotnik JP; Wilcox D; Zhang L; Bui MH; Sheppard GS; Wang L; Sehgal V; Lin X; Huang X; Lu X; Uziel T; Hessler P; Lam LT; Bellin RJ; Mehta G; Fidanze S; Pratt JK; Liu D; Hasvold LA; Sun C; Panchal SC; Nicolette JJ; Fossey SL; Park CH; Longenecker K; Bigelow L; Torrent M; Rosenberg SH; Kati WM; Shen Y
Nature; 2020 Feb; 578(7794):306-310. PubMed ID: 31969702
[TBL] [Abstract][Full Text] [Related]
22. The Bromodomain protein BRD4 controls HOTAIR, a long noncoding RNA essential for glioblastoma proliferation.
Pastori C; Kapranov P; Penas C; Peschansky V; Volmar CH; Sarkaria JN; Bregy A; Komotar R; St Laurent G; Ayad NG; Wahlestedt C
Proc Natl Acad Sci U S A; 2015 Jul; 112(27):8326-31. PubMed ID: 26111795
[TBL] [Abstract][Full Text] [Related]
23. BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extraterminal Domain Proteins, in Patients with Selected Advanced Solid Tumors: Results from a Phase 1/2a Trial.
Hilton J; Cristea M; Postel-Vinay S; Baldini C; Voskoboynik M; Edenfield W; Shapiro GI; Cheng ML; Vuky J; Corr B; Das S; Apfel A; Xu K; Kozicki M; Ünsal-Kaçmaz K; Hammell A; Wang G; Ravindran P; Kollia G; Esposito O; Coker S; Diamond JR
Cancers (Basel); 2022 Aug; 14(17):. PubMed ID: 36077617
[TBL] [Abstract][Full Text] [Related]
24. Physachenolide C is a Potent, Selective BET Inhibitor.
Zerio CJ; Sivinski J; Wijeratne EMK; Xu YM; Ngo DT; Ambrose AJ; Villa-Celis L; Ghadirian N; Clarkson MW; Zhang DD; Horton NC; Gunatilaka AAL; Fromme R; Chapman E
J Med Chem; 2023 Jan; 66(1):913-933. PubMed ID: 36577036
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery.
Fu LL; Tian M; Li X; Li JJ; Huang J; Ouyang L; Zhang Y; Liu B
Oncotarget; 2015 Mar; 6(8):5501-16. PubMed ID: 25849938
[TBL] [Abstract][Full Text] [Related]
26. Privileged Scaffolds Targeting Bromodomain-containing Protein 4.
Wang R; Wang YA; Xu YG; Shi L
Curr Top Med Chem; 2022; 22(7):600-627. PubMed ID: 35139799
[TBL] [Abstract][Full Text] [Related]
27. Role of bromodomain and extraterminal (BET) proteins in prostate cancer.
Mandl A; Markowski MC; Carducci MA; Antonarakis ES
Expert Opin Investig Drugs; 2023 Mar; 32(3):213-228. PubMed ID: 36857796
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of the BET family reduces its new target gene IDO1 expression and the production of L-kynurenine.
Tian CQ; Chen L; Chen HD; Huan XJ; Hu JP; Shen JK; Xiong B; Wang YQ; Miao ZH
Cell Death Dis; 2019 Jul; 10(8):557. PubMed ID: 31324754
[TBL] [Abstract][Full Text] [Related]
29. Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors.
Ran X; Zhao Y; Liu L; Bai L; Yang CY; Zhou B; Meagher JL; Chinnaswamy K; Stuckey JA; Wang S
J Med Chem; 2015 Jun; 58(12):4927-39. PubMed ID: 26080064
[TBL] [Abstract][Full Text] [Related]
30. BET proteins: Biological functions and therapeutic interventions.
Guo J; Zheng Q; Peng Y
Pharmacol Ther; 2023 Mar; 243():108354. PubMed ID: 36739915
[TBL] [Abstract][Full Text] [Related]
31. Selective N-Terminal BET Bromodomain Inhibitors by Targeting Non-Conserved Residues and Structured Water Displacement*.
Cui H; Divakaran A; Pandey AK; Johnson JA; Zahid H; Hoell ZJ; Ellingson MO; Shi K; Aihara H; Harki DA; Pomerantz WCK
Angew Chem Int Ed Engl; 2021 Jan; 60(3):1220-1226. PubMed ID: 32975004
[TBL] [Abstract][Full Text] [Related]
32. Recent Developments in Targeting Bromodomain and Extra Terminal Domain Proteins for Cancer Therapeutics.
Cai M; Dong J; Li H; Qin JJ
Curr Med Chem; 2022; 29(25):4391-4409. PubMed ID: 35152859
[TBL] [Abstract][Full Text] [Related]
33. Small-molecule PROTAC degraders of the Bromodomain and Extra Terminal (BET) proteins - A review.
Yang CY; Qin C; Bai L; Wang S
Drug Discov Today Technol; 2019 Apr; 31():43-51. PubMed ID: 31200858
[TBL] [Abstract][Full Text] [Related]
34. BET Bromodomain Proteins Brd2, Brd3 and Brd4 Selectively Regulate Metabolic Pathways in the Pancreatic β-Cell.
Deeney JT; Belkina AC; Shirihai OS; Corkey BE; Denis GV
PLoS One; 2016; 11(3):e0151329. PubMed ID: 27008626
[TBL] [Abstract][Full Text] [Related]
35. Anticancer Effects of I-BET151, an Inhibitor of Bromodomain and Extra-Terminal Domain Proteins.
Lai J; Liu Z; Zhao Y; Ma C; Huang H
Front Oncol; 2021; 11():716830. PubMed ID: 34540687
[TBL] [Abstract][Full Text] [Related]
36. Combined Targeting of the BRD4-NUT-p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734.
Morrison-Smith CD; Knox TM; Filic I; Soroko KM; Eschle BK; Wilkens MK; Gokhale PC; Giles F; Griffin A; Brown B; Shapiro GI; Zucconi BE; Cole PA; Lemieux ME; French CA
Mol Cancer Ther; 2020 Jul; 19(7):1406-1414. PubMed ID: 32371576
[TBL] [Abstract][Full Text] [Related]
37. Bromodomain and extraterminal proteins suppress NF-E2-related factor 2-mediated antioxidant gene expression.
Michaeloudes C; Mercado N; Clarke C; Bhavsar PK; Adcock IM; Barnes PJ; Chung KF
J Immunol; 2014 May; 192(10):4913-4920. PubMed ID: 24733848
[TBL] [Abstract][Full Text] [Related]
38. A Comprehensive Review of BET Protein Biochemistry, Physiology, and Pathological Roles.
Ali HA; Li Y; Bilal AHM; Qin T; Yuan Z; Zhao W
Front Pharmacol; 2022; 13():818891. PubMed ID: 35401196
[TBL] [Abstract][Full Text] [Related]
39. Bromodomain and extraterminal domain protein bromodomain inhibitor based cancer therapeutics.
Halder TG; Soldi R; Sharma S
Curr Opin Oncol; 2021 Sep; 33(5):526-531. PubMed ID: 34280171
[TBL] [Abstract][Full Text] [Related]
40. Bromodomain and extraterminal domain-containing protein inhibition attenuates acute inflammation after spinal cord injury.
Rudman MD; Choi JS; Lee HE; Tan SK; Ayad NG; Lee JK
Exp Neurol; 2018 Nov; 309():181-192. PubMed ID: 30134146
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
